Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

non-squamous non-small cell lung cancer

  • You have access
    Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer
    MASAHIRO YAMASAKI, ISAO MURAKAMI, KIKUO NAKANO, MIHOKO DOI, SOUICHI KITAGUCHI, TOMOHIRO KONDO, JOJI SAKURAI, NOBORU HATTORI and KEN-ICHI ARITA
    Anticancer Research February 2017, 37 (2) 923-928;
  • You have access
    CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy
    KAZUKI SONE, TETSUYA OGURI, MAKOTO NAKAO, YUSUKE KAGAWA, RYOTA KUROWAKA, HIROMI FURUTA, SATOSHI FUKUDA, TAKEHIRO UEMURA, OSAMU TAKAKUWA, YOSHIHIRO KANEMITSU, HIROTSUGU OHKUBO, MASAYA TAKEMURA, KEN MAENO, YUTAKA ITO, HIDEFUMI SATO, HIDEKI MURAMATSU and AKIO NIIMI
    Anticancer Research February 2017, 37 (2) 935-939;
  • You have access
    Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906
    TOMOKI KIMURA, HIROYUKI TANIGUCHI, NAOHIRO WATANABE, HIDEO SAKA, YOSHIHITO KOGURE, JOE SHINDO, TOMOHIKO OGASAWARA, EIJI KOJIMA, YOSHINORI HASEGAWA, MASASHI YAMAMOTO, RYUJIRO SUZUKI, MASAHIKO ANDO, MASASHI KONDO and HIROSHI SAITO
    Anticancer Research April 2016, 36 (4) 1767-1771;
  • You have access
    Bevacizumab plus Weekly Paclitaxel with or Without Carboplatin for Previously-treated Non-squamous Non-Small Cell Lung Cancer
    AKITO HATA, NOBUYUKI KATAKAMI, KOSUKE TANAKA, JUMPEI TAKESHITA, TAKESHI MATSUMOTO, KAZUYA MONDEN, KAZUMA NAGATA, KATSUHIRO MASAGO, REIKO KAJI, SHIRO FUJITA, RYO TACHIKAWA, KYOKO OTSUKA, KOJIRO OTSUKA and KEISUKE TOMII
    Anticancer Research January 2014, 34 (1) 275-281;
  • You have access
    Phase II trial of Pemetrexed Continuation – Maintenance after Carboplatin-based Induction in Untreated Non-squamous Non-small Cell Lung Cancer
    SEIGO MINAMI, TAKASHI KIJIMA, KIYOSHI KOMUTA, TORU KUMAGAI, FUMIO IMAMURA, SOICHIRO YOKOTA, YOSHIKO TAKEUCHI, TAKESHI NAKATANI, ISAO TACHIBANA and ICHIRO KAWASE
    Anticancer Research December 2013, 33 (12) 5535-5542;
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire